Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Cardiac effort is less variable than six-minute walk distance, correlates with hemodynamics and is consistent with REVEAL 2.0 risk score in a sub-study of the TORREY phase 2 PAH trial

Wednesday, May 22, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: A sub-study of the TORREY phase 2 PAH trial indicates that cardiac effort is more consistent than the six-minute walk distance. This finding correlates with hemodynamic data and is consistent with the REVEAL 2.0 risk score. The results suggest that cardiac effort may be a reliable measure in assessing patients with pulmonary arterial hypertension (PAH).
Price reaction · baseline $0.67 (2024-05-21 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close · peak
-4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Cardiac effort shows less variability compared to six-minute walk distance.
  • Findings correlate well with hemodynamic measurements.
  • Results align with the REVEAL 2.0 risk score.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Cardiac effort is less variable than six-minute walk distance, correlates with hemodynamics and is consistent with REVEAL 2.0 risk score in a sub-study of the TORREY phase 2 PAH trial
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the main finding of the TORREY phase 2 trial?

The trial found that cardiac effort is less variable than the six-minute walk distance.

How does cardiac effort relate to hemodynamics?

Cardiac effort correlates well with hemodynamic measurements in patients.

What risk score is consistent with the trial's findings?

The findings are consistent with the REVEAL 2.0 risk score.

What condition is being studied in the TORREY trial?

The trial studies pulmonary arterial hypertension (PAH).

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare TORREY trial cardiac effort pulmonary arterial hypertension REVEAL 2.0
Last updated: May 22, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →